VRT106

Phase 2Small molecule

GGuangzhou Virotech Pharmaceutical Co., Ltd.

VRT106 is one of 53 small molecule programs targeting Gastric Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastric CancerActive, not recruiting

GlioblastomaActive, not recruiting

Gastric CancerPhase 2

Active, not recruiting

GlioblastomaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

714 competitors in Gastric Cancer

#DrugCompanyPhaseTrials

Docetaxel for Injection (albumin-Bound)

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 3

2 2

S-1/cisplatin

Taiho Oncology, Inc.

Phase 3

2 3

Gemzar

Johnson & Johnson

Preclinical

—4

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

3 5

VRT106

GGuangzhou Virotech Pharmaceutical Co., Ltd.

Phase 2

1 6

S1,

CChinese Academy of Medical Sciences

Preclinical

17 7

PD-1 Inhibitor

Johnson & Johnson

Preclinical

3 8

Induction Phase1

Genmab

Preclinical

1 9

Glutamine

Sanofi

Preclinical

1 10

Human Albumin

TTonghua Anrate Biopharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Patients With Solid Tumors

NCT06368921

Q1 2027

Phase 1Recruiting

Locally Advanced or Metastatic Solid Tumors

NCT06826313

Q2 2029

Phase 2Not yet recruiting

Gastric Cancer

NCT07486310

Phase 1/2Recruiting

Glioblastoma

NCT07093814

Clinical

Trials by Indication[1]

Locally Advanced or Metastatic Solid Tumors1 trial

A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid Tumors

Recruiting·GGuangzhou Virotech Pharmaceutical Co., Ltd.·Phase 1·NCT06826313·12 enrolled

Gastric Cancer1 trial

Evaluation of Pressurized Intraperitoneal Aerosol Chemotherapy With VRT106 Versus PIPAC in Patients With Advanced Gastric Cancer and PeritonealMetastasis: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial

Not yet recruiting·GGuangdong Provincial People's Hospital·Phase 2·NCT07486310·30 enrolled

Glioblastoma1 trial

A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma

Recruiting·GGuangzhou Virotech Pharmaceutical Co., Ltd.·Phase 1/2·NCT07093814·42 enrolled

Patients With Solid Tumors1 trial

A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors

Recruiting·GGuangzhou Virotech Pharmaceutical Co., Ltd.·Phase 1·NCT06368921·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for VRT106. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VRT106 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VRT106. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Guangzhou Virotech Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GGuangzhou Virotech Pharmaceutical Co., Ltd.

VRT106

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2029

Trials by Indication[1]

Locally Advanced or Metastatic Solid Tumors1 trial

Gastric Cancer1 trial

Glioblastoma1 trial

Patients With Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News